B Cells, T Cells and Inflammatory CSF Biomarkers in Primary Progressive MS and Relapsing MS in the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Trial (1635)

Objective: null To assess longitudinal changes in B cells, T cells, neurofilament light (NfL) and soluble inflammatory markers in patients with primary progressive (PPMS) and relapsing (RMS) multiple sclerosis following ocrelizumab (OCR) treatment. null Background: null OCR, an anti-CD20 molecule, reduces progression in MS. Less is known about biomarkers and mechanisms of anti-CD20 action in PPMS than in RMS. Presence of T1 gadolinium–enhancing...